Prostaglandins as a Topical Therapy for Erectile Dysfunction: A Comprehensive Review.


Journal

Sexual medicine reviews
ISSN: 2050-0521
Titre abrégé: Sex Med Rev
Pays: Netherlands
ID NLM: 101614773

Informations de publication

Date de publication:
10 2022
Historique:
received: 29 03 2022
revised: 05 06 2022
accepted: 09 06 2022
entrez: 9 10 2022
pubmed: 10 10 2022
medline: 12 10 2022
Statut: ppublish

Résumé

Erectile dysfunction (ED) is a substantial cause of dissatisfaction among many men. This discontentment has led to the emergence of various drug treatment options for this problem. Unfortunately, due to various interactions, contraindications, and side effects, systemic therapies such as phosphodiesterase-5 inhibitors (including sildenafil, tadalafil, vardenafil, avanafil, etc.) are not welcomed in many patients. These problems have led researchers to look for other ways to reduce these complications. This article holistically reviews the efficacy of topical prostaglandins and their role in treating ED. We sought to provide a comprehensive overview of recent findings on the current topic by using the extensive literature search to identify the latest scientific reports on the topic. In this regard, topical and transdermal treatments can be suitable alternatives. In diverse studies, prostaglandins, remarkably PGE1 (also known as alprostadil), have been suggested to be an acceptable candidate for topical treatment. Numerous formulations of PGE1 have been used to treat patients so far. Still, in general, with the evolution of classical formulation methods toward modern techniques (such as using nanocarriers and skin permeability enhancers), the probability of treatment success also increases. Hamzehnejadi M, Tavakoli MR, Homayoun F et al. Prostaglandins as a Topical Therapy for Erectile Dysfunction: A Comprehensive Review. Sex Med Rev 2022;10:764-781.

Identifiants

pubmed: 36210096
pii: S2050-0521(22)00054-3
doi: 10.1016/j.sxmr.2022.06.004
pii:
doi:

Substances chimiques

Prostaglandins 0
Vardenafil Dihydrochloride 5O8R96XMH7
Tadalafil 742SXX0ICT
Sildenafil Citrate BW9B0ZE037
Cyclic Nucleotide Phosphodiesterases, Type 5 EC 3.1.4.35
Alprostadil F5TD010360

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

764-781

Informations de copyright

Copyright © 2022 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Auteurs

Mohammadsadegh Hamzehnejadi (M)

Pharmaceutical Sciences and Cosmetic Products Research Center, Kerman University of Medical Sciences, Kerman, Iran.

Marziye Ranjbar Tavakoli (MR)

Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran.

Fatemeh Homayouni (F)

Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran.

Zahra Jahani (Z)

Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran.

Masoud Rezaei (M)

Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

Mohammad Amin Langarizadeh (MA)

Pharmaceutical Sciences and Cosmetic Products Research Center, Kerman University of Medical Sciences, Kerman, Iran; Department of Medicinal Chemistry, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.

Hamid Forootanfar (H)

Pharmaceutical Sciences and Cosmetic Products Research Center, Kerman University of Medical Sciences, Kerman, Iran. Electronic address: h_forootanfar@kmu.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH